

## Special Issue

# Advances in Cardiovascular Pharmacology: The Era of Targeted Therapies in Cardiology

### Message from the Guest Editors

Cardiovascular diseases (CVDs) are the leading cause of death worldwide. Specifically, cardiovascular pharmacology is now facing a new approach to cardiac diseases: the molecular “influence” of gene transcription and transduction in order to target the inner mechanism which could be responsible for the onset and progression of CVDs. Recent innovations in the field of non-invasive treatment of CVDs are focusing on three main issues: 1. specifically identifying and treating the core cause of the illness; 2. avoiding adverse events related to pharmacological treatments; 3. improving adherence to and persistence on therapies. The aim of this Special Issue is to provide a dedicated overview of new pharmacological approaches to CVDs. Authors are invited to contribute original basic research, prospective studies, and systematic reviews in the field of pharmacological approaches to cardiac and vascular diseases by outlining the most recent advances in therapies and treatments.

### Guest Editors

Prof. Dr. Pietro Scicchitano

Cardiology Department, Perinei Hospital, Bari, Italy

Dr. Francesco Massari

Cardiology Department, Perinei Hospital, Bari, Italy

### Deadline for manuscript submissions

closed (30 June 2022)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/100095](https://mdpi.com/si/100095)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).